SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

被引:0
|
作者
Schmidt, Timothy [1 ]
Gahvari, Zhubin [1 ]
Callander, Natalie S. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA
关键词
MGUS; MM; Risk stratification; Screening; SMM; INDEPENDENT RISK-FACTOR; LIGHT-CHAIN RATIO; MASS-SPECTROMETRY; BONE-MARROW; PROGRESSION; MGUS; LENALIDOMIDE; PREVALENCE; ABNORMALITIES; POPULATION;
D O I
10.1016/j.clml.2024.03.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. In this review, we summarize the current diagnosis treatment guidelines for MGUS and SMM and highlight recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.
引用
收藏
页码:653 / 664
页数:12
相关论文
共 50 条
  • [41] Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
    Wadhera, Rishi K.
    Kyle, Robert A.
    Larson, Dirk R.
    Dispenzieri, Angela
    Kumar, Shaji
    Lazarus, Hillard M.
    Rajkumar, S. Vincent
    BLOOD, 2011, 118 (11) : 2985 - 2987
  • [42] Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Vachon, Celine M.
    Kyle, Robert A.
    Therneau, Terry M.
    Foreman, Barbara J.
    Larson, Dirk R.
    Colby, Colin L.
    Phelps, Tara K.
    Dispenzieri, Angela
    Kumar, Shaji K.
    Katzmann, Jerry A.
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (04) : 785 - 790
  • [43] Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma
    Neriishi, K
    Nakashima, E
    Suzuki, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) : 405 - 410
  • [44] Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma
    Salem, Dalia Abdel-Raouf
    Korde, Neha
    Venzon, David J.
    Liewehr, David J.
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul
    Tembhare, Prashant R.
    Yuan, Constance M.
    Landgren, Carl Ola
    Stetler-Stevenson, Maryalice
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 178 - 186
  • [45] Distinct Nuclear Organization of Telomeres and Centromeres in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
    Yu, Pak Lok Ivan
    Wang, Rachel R.
    Johnston, Grace
    Wang, Yaqiong
    Tammur, Pille
    Tamm, Anu
    Punab, Mari
    Rangel-Pozzo, Aline
    Mai, Sabine
    CELLS, 2019, 8 (07)
  • [46] Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma
    Donovan, KA
    Lacy, MQ
    Kline, MP
    Ahmann, GJ
    Heimbach, JK
    Kyle, RA
    Lust, JA
    LEUKEMIA, 1998, 12 (04) : 593 - 600
  • [47] Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    Landgren, Ola
    Kyle, Robert A.
    Pfeiffer, Ruth M.
    Katzmann, Jerry A.
    Caporaso, Neil E.
    Hayes, Richard B.
    Dispenzieri, Angela
    Kumar, Shaji
    Clark, Raynell J.
    Baris, Dalsu
    Hoover, Robert
    Rajkumar, S. Vincent
    BLOOD, 2009, 113 (22) : 5412 - 5417
  • [48] Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
    Landgren, Ola
    Hofmann, Jonathan N.
    McShane, Charlene M.
    Santo, Loredana
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Kazandjian, Dickran
    Murata, Kazunori
    Thoren, Katie
    Ramanathan, Lakshmi
    Dogan, Ahmet
    Rustad, Even
    Lu, Sydney X.
    Akhlaghi, Theresia
    Kristinsson, Sigurdur Y.
    Bjorkholm, Magnus
    Devlin, Sean
    Purdue, Mark P.
    Pfeiffer, Ruth M.
    Turesson, Ingemar
    JAMA ONCOLOGY, 2019, 5 (09) : 1293 - 1301
  • [49] Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma
    KA Donovan
    MQ Lacy
    MP Kline
    GJ Ahmann
    JK Heimbach
    RA Kyle
    JA Lust
    Leukemia, 1998, 12 : 593 - 600
  • [50] Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
    Isgor, Irem Sahver
    Toptas, Tayfur
    Turkoz, Huseyin Kemal
    TURKISH JOURNAL OF HEMATOLOGY, 2022, 39 (04) : 245 - 253